Disrupting Roquin-1 interaction with Regnase-1 induces autoimmunity and enhances antitumor responses.


Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
12 2021
Historique:
received: 29 06 2020
accepted: 30 09 2021
pubmed: 24 11 2021
medline: 30 12 2021
entrez: 23 11 2021
Statut: ppublish

Résumé

Roquin and Regnase-1 proteins bind and post-transcriptionally regulate proinflammatory target messenger RNAs to maintain immune homeostasis. Either the sanroque mutation in Roquin-1 or loss of Regnase-1 cause systemic lupus erythematosus-like phenotypes. Analyzing mice with T cells that lack expression of Roquin-1, its paralog Roquin-2 and Regnase-1 proteins, we detect overlapping or unique phenotypes by comparing individual and combined inactivation. These comprised spontaneous activation, metabolic reprogramming and persistence of T cells leading to autoimmunity. Here, we define an interaction surface in Roquin-1 for binding to Regnase-1 that included the sanroque residue. Mutations in Roquin-1 impairing this interaction and cooperative regulation of targets induced T follicular helper cells, germinal center B cells and autoantibody formation. These mutations also improved the functionality of tumor-specific T cells by promoting their accumulation in the tumor and reducing expression of exhaustion markers. Our data reveal the physical interaction of Roquin-1 with Regnase-1 as a hub to control self-reactivity and effector functions in immune cell therapies.

Identifiants

pubmed: 34811541
doi: 10.1038/s41590-021-01064-3
pii: 10.1038/s41590-021-01064-3
pmc: PMC8996344
mid: NIHMS1779511
doi:

Substances chimiques

Repressor Proteins 0
roquin-2 protein, mouse 0
Rc3h1 protein, mouse EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
Ribonucleases EC 3.1.-
Zc3h12a protein, mouse EC 3.1.-

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1563-1576

Subventions

Organisme : NIAID NIH HHS
ID : R15 AI138116
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Pratama, A. et al. Roquin-2 shares functions with its paralog Roquin-1 in the repression of mRNAs controlling T follicular helper cells and systemic inflammation. Immunity 38, 669–680 (2013).
pubmed: 23583642 doi: 10.1016/j.immuni.2013.01.011
Tavernier, S. J. et al. A human immune dysregulation syndrome characterized by severe hyperinflammation with a homozygous nonsense Roquin-1 mutation. Nat. Commun. 10, 4779 (2019).
pubmed: 31636267 pmcid: 6803705 doi: 10.1038/s41467-019-12704-6
Vogel, K. U. et al. Roquin paralogs 1 and 2 redundantly repress the Icos and Ox40 costimulator mRNAs and control follicular helper T cell differentiation. Immunity 38, 655–668 (2013).
pubmed: 23583643 doi: 10.1016/j.immuni.2012.12.004
Matsushita, K. et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458, 1185–1190 (2009).
pubmed: 19322177 doi: 10.1038/nature07924
Uehata, T. et al. Malt1-induced cleavage of regnase-1 in CD4
Jeltsch, K. M. et al. Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(
pubmed: 25282160 doi: 10.1038/ni.3008
Mino, T. et al. Regnase-1 and Roquin regulate a common element in inflammatory mRNAs by spatiotemporally distinct mechanisms. Cell 161, 1058–1073 (2015).
pubmed: 26000482 doi: 10.1016/j.cell.2015.04.029
Jeltsch, K. M. & Heissmeyer, V. Regulation of T cell signaling and autoimmunity by RNA-binding proteins. Curr. Opin. Immunol. 39, 127–135 (2016).
pubmed: 26871597 doi: 10.1016/j.coi.2016.01.011
Leppek, K. et al. Roquin promotes constitutive mRNA decay via a conserved class of stem-loop recognition motifs. Cell 153, 869–881 (2013).
pubmed: 23663784 doi: 10.1016/j.cell.2013.04.016
Glasmacher, E. et al. Roquin binds inducible costimulator mRNA and effectors of mRNA decay to induce microRNA-independent post-transcriptional repression. Nat. Immunol. 11, 725–733 (2010).
pubmed: 20639877 doi: 10.1038/ni.1902
Sgromo, A. et al. A CAF40-binding motif facilitates recruitment of the CCR4-NOT complex to mRNAs targeted by Drosophila Roquin. Nat. Commun. 8, 14307 (2017).
pubmed: 28165457 pmcid: 5303829 doi: 10.1038/ncomms14307
Mino, T. et al. Translation-dependent unwinding of stem-loops by UPF1 licenses Regnase-1 to degrade inflammatory mRNAs. Nucleic Acids Res. 47, 8838–8859 (2019).
pubmed: 31329944 pmcid: 7145602
Fu, M. & Blackshear, P. J. RNA-binding proteins in immune regulation: a focus on CCCH zinc finger proteins. Nat. Rev. Immunol. 17, 130–143 (2017).
pubmed: 27990022 doi: 10.1038/nri.2016.129
Vinuesa, C. G. et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435, 452–458 (2005).
pubmed: 15917799 doi: 10.1038/nature03555
Akira, S. Regnase-1, a ribonuclease involved in the regulation of immune responses. Cold Spring Harb. Symp. Quant. Biol. 78, 51–60 (2013).
pubmed: 24163394 doi: 10.1101/sqb.2013.78.019877
Heissmeyer, V. & Vogel, K. U. Molecular control of T
pubmed: 23550652 doi: 10.1111/imr.12056
von Gamm, M. et al. Immune homeostasis and regulation of the interferon pathway require myeloid-derived Regnase-3. J. Exp. Med. 216, 1700–1723 (2019).
doi: 10.1084/jem.20181762
Wei, J. et al. Targeting Regnase-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471–476 (2019).
pubmed: 31827283 pmcid: 6937596 doi: 10.1038/s41586-019-1821-z
Zheng, W. et al. Regnase-1 suppresses TCF-1
pubmed: 33690816 doi: 10.1182/blood.2020009309
Li, Y. et al. Central role of myeloid MCPIP1 in protecting against LPS-induced inflammation and lung injury. Signal Transduct. Target Ther. 2, 17066 (2017).
pubmed: 29263935 pmcid: 5721545 doi: 10.1038/sigtrans.2017.66
Bertossi, A. et al. Loss of Roquin induces early death and immune deregulation but not autoimmunity. J. Exp. Med. 208, 1749–1756 (2011).
pubmed: 21844204 pmcid: 3171092 doi: 10.1084/jem.20110578
Cui, X. et al. Regnase-1 and Roquin nonredundantly regulate T
pubmed: 29127149 doi: 10.4049/jimmunol.1701211
Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007).
pubmed: 17251932 doi: 10.1038/nature05541
Sledzinska, A. TGF-β signalling is required for CD4
pubmed: 24115907 pmcid: 3792861 doi: 10.1371/journal.pbio.1001674
Zeitrag, J., Alterauge, D., Dahlstrom, F. & Baumjohann, D. Gene dose matters: considerations for the use of inducible CD4-CreER(T2) mouse lines. Eur. J. Immunol. 50, 603–605 (2020).
pubmed: 32087088 doi: 10.1002/eji.201948461
Hudson, W. H. et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1
pubmed: 31810882 pmcid: 6920571 doi: 10.1016/j.immuni.2019.11.002
McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev. Immunol. 37, 457–495 (2019).
pubmed: 30676822 doi: 10.1146/annurev-immunol-041015-055318
Yu, D. et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 450, 299–303 (2007).
pubmed: 18172933 doi: 10.1038/nature06253
Tan, A. H., Wong, S. C. & Lam, K. P. Regulation of mouse inducible costimulator (ICOS) expression by Fyn-NFATc2 and ERK signaling in T cells. J. Biol. Chem. 281, 28666–28678 (2006).
pubmed: 16880206 doi: 10.1074/jbc.M604081200
Iwasaki, H. et al. The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat. Immunol. 12, 1167–1175 (2011).
pubmed: 22037600 doi: 10.1038/ni.2137
Janowski, R. et al. Roquin recognizes a non-canonical hexaloop structure in the 3′-UTR of Ox40. Nat. Commun. 7, 11032 (2016).
pubmed: 27010430 pmcid: 5603727 doi: 10.1038/ncomms11032
Schlundt, A. et al. Structural basis for RNA recognition in roquin-mediated post-transcriptional gene regulation. Nat. Struct. Mol. Biol. 21, 671–678 (2014).
pubmed: 25026077 doi: 10.1038/nsmb.2855
Srivastava, M. et al. Roquin binds microRNA-146a and Argonaute2 to regulate microRNA homeostasis. Nat. Commun. 6, 6253 (2015).
pubmed: 25697406 doi: 10.1038/ncomms7253
Tan, D., Zhou, M., Kiledjian, M. & Tong, L. The ROQ domain of Roquin recognizes mRNA constitutive-decay element and double-stranded RNA. Nat. Struct. Mol. Biol. 21, 679–685 (2014).
pubmed: 25026078 pmcid: 4125485 doi: 10.1038/nsmb.2857
Suzuki, H. I. et al. MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol. Cell 44, 424–436 (2011).
pubmed: 22055188 doi: 10.1016/j.molcel.2011.09.012
Lee, S. K. et al. Interferon-γ excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 37, 880–892 (2012).
pubmed: 23159227 doi: 10.1016/j.immuni.2012.10.010
Ellyard, J. I. et al. Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. Blood 120, 812–821 (2012).
pubmed: 22700722 doi: 10.1182/blood-2011-07-365130
Blank, C. U. et al. Defining ‘T cell exhaustion’. Nat. Rev. Immunol. 19, 665–674 (2019).
pubmed: 31570879 pmcid: 7286441 doi: 10.1038/s41577-019-0221-9
Essig, K. et al. Roquin targets mRNAs in a 3′-UTR-specific manner by different modes of regulation. Nat. Commun. 9, 3810 (2018).
pubmed: 30232334 pmcid: 6145892 doi: 10.1038/s41467-018-06184-3
Murakawa, Y. et al. RC3H1 post-transcriptionally regulates A20 mRNA and modulates the activity of the IKK/NF-κB pathway. Nat. Commun. 6, 7367 (2015).
pubmed: 26170170 doi: 10.1038/ncomms8367
Song, J. et al. Human cytomegalovirus induces and exploits Roquin to counteract the IRF1-mediated antiviral state. Proc. Natl Acad. Sci. USA 116, 18619–18628 (2019).
pubmed: 31451648 pmcid: 6744924 doi: 10.1073/pnas.1909314116
Essig, K. et al. Roquin suppresses the PI3K-mTOR signaling pathway to inhibit T helper cell differentiation and conversion of T
pubmed: 29246441 doi: 10.1016/j.immuni.2017.11.008
Nagahama, Y. et al. Regnase-1 controls colon epithelial regeneration via regulation of mTOR and purine metabolism. Proc. Natl Acad. Sci. USA 115, 11036–11041 (2018).
pubmed: 30297433 pmcid: 6205455 doi: 10.1073/pnas.1809575115
Hoefig, K. P. et al. Defining the RBPome of primary T helper cells to elucidate higher-order Roquin-mediated mRNA regulation. Nat. Commun. 12, 5208 (2021).
pubmed: 34471108 pmcid: 8410761 doi: 10.1038/s41467-021-25345-5
Lee, P. P. et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15, 763–774 (2001).
pubmed: 11728338 doi: 10.1016/S1074-7613(01)00227-8
Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17–27 (1994).
pubmed: 8287475 doi: 10.1016/0092-8674(94)90169-4
Hochedlinger, K., Yamada, Y., Beard, C. & Jaenisch, R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121, 465–477 (2005).
pubmed: 15882627 doi: 10.1016/j.cell.2005.02.018
Schieweck, R. et al. Pumilio2 and Staufen2 selectively balance the synaptic proteome. Cell Rep. 35, 109279 (2021).
pubmed: 34161769 doi: 10.1016/j.celrep.2021.109279
Digman, M. A., Caiolfa, V. R., Zamai, M. & Gratton, E. The phasor approach to fluorescence lifetime imaging analysis. Biophys. J. 94, L14–L16 (2008).
pubmed: 17981902 doi: 10.1529/biophysj.107.120154

Auteurs

Gesine Behrens (G)

Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität in Munich, Planegg-Martinsried, Germany.

Stephanie L Edelmann (SL)

Research Unit Molecular Immune Regulation, Helmholtz Zentrum München, Munich, Germany.

Timsse Raj (T)

Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität in Munich, Planegg-Martinsried, Germany.

Nina Kronbeck (N)

Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität in Munich, Planegg-Martinsried, Germany.

Thomas Monecke (T)

Institute of Pharmaceutical Biotechnology, Ulm University, Ulm, Germany.

Elena Davydova (E)

Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, Germany.

Elaine H Wong (EH)

Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität in Munich, Planegg-Martinsried, Germany.

Lisa Kifinger (L)

Research Unit Molecular Immune Regulation, Helmholtz Zentrum München, Munich, Germany.

Florian Giesert (F)

Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.

Martin E Kirmaier (ME)

Cancer and Immunometabolism Research Group at the Gene Center, Ludwig-Maximilians-Universität in Munich, Munich, Germany.
Department of Medicine III, LMU University Hospital, Ludwig-Maximilians-Universität in Munich, Munich, Germany.

Christine Hohn (C)

Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität in Munich, Planegg-Martinsried, Germany.

Laura S de Jonge (LS)

Research Unit Molecular Immune Regulation, Helmholtz Zentrum München, Munich, Germany.

Mariano Gonzalez Pisfil (MG)

Core Facility Bioimaging and Walter-Brendel-Centre of Experimental Medicine at the Biomedical Center, Ludwig-Maximilians-Universität in Munich, Planegg-Martinsried, Germany.

Mingui Fu (M)

Department of Basic Medical Science, School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.

Sebastian Theurich (S)

Cancer and Immunometabolism Research Group at the Gene Center, Ludwig-Maximilians-Universität in Munich, Munich, Germany.
Department of Medicine III, LMU University Hospital, Ludwig-Maximilians-Universität in Munich, Munich, Germany.

Stefan Feske (S)

Department of Pathology, New York University School of Medicine, New York, NY, USA.

Naoto Kawakami (N)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians-Universität in Munich, Planegg-Martinsried, Germany.

Wolfgang Wurst (W)

Institute of Developmental Genetics, Helmholtz Zentrum München, Neuherberg, Germany.
German Center for Neurodegenerative Diseases (DZNE) Site Munich, Munich, Germany.
Technische Universität München, Lehrstuhl für Entwicklungsgenetik c/o Helmholtz Zentrum München, Munich, Germany.

Dierk Niessing (D)

Institute of Pharmaceutical Biotechnology, Ulm University, Ulm, Germany.
Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, Germany.

Vigo Heissmeyer (V)

Institute for Immunology, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität in Munich, Planegg-Martinsried, Germany. vigo.heissmeyer@med.uni-muenchen.de.
Research Unit Molecular Immune Regulation, Helmholtz Zentrum München, Munich, Germany. vigo.heissmeyer@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH